Cancer diagnostics company Pacific Edge today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida. Taking the podium, Pacific Edge will host a Symposium on the current and future use of molecular biomarkers in the detection and surveillance of non-muscle invasive bladder cancer (NMIBC). Alongside the Symposium, Pacific Edge will lead a Principle Investigator Meeting for its DRIVE study – a study focused on Cxbladder validation in a veterans cohort across multiple VA sites for which it plans to conclude enrolment in 2023.
HERSHEY, Pa., March 9, 2023 /PRNewswire-PRWeb/ -- Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida.
The SESAUA meeting is the largest of the AUA sectional meetings, hosting urologists and other urological experts from the nine southeastern US states, Panama, Puerto Rico and the US Virgin Islands. As a key theme at this year's conference, discussion will include a focus on leading strategies for the evaluation and management of urologic oncology patients, including those with bladder cancer.
Taking the podium, Pacific Edge will host a Symposium, scheduled for 12pm EST Thursday March 16, on the current and future use of molecular biomarkers in the detection and surveillance of non-muscle invasive bladder cancer (NMIBC). The session, led by Pacific Edge VP of Medical Affairs, Dr. Tamer Aboushwareb, will feature a keynote address from Dr. Sia Daneshmand, Professor of Urology and Director Clinical Research at the Keck School of Medicine, USC, and will culminate in a panel discussion including Q&A from the audience.
Alongside the Symposium, Pacific Edge will lead a Principle Investigator Meeting for the DRIVE study – a study focused on Cxbladder validation in a veterans cohort across multiple VA sites for which it plans to conclude enrolment in 2023. With the objective being to support the streamlined completion of the study, trial coordinators will use the session to share successes and address challenges linked to recruitment. "Concluding DRIVE will not only validate Cxbladder in a Veteran's cohort, but also double as the first clinical validation of Cxbladder Detect+ in any patient cohort," says Dr. Aboushwareb. "Validation of Cxbladder Detect+ remains one of our most important commercial milestones as the company looks to seek coding, coverage and pricing in the coming months."
Media Contact
Peter Meintjes, Chief Executive, Pacific Edge Ltd, 64 022 032 1263, [email protected]
Richard Inder, The Project, 021 645 643, [email protected]
SOURCE Pacific Edge Ltd
Share this article